LISRAYA

This brand name is authorized in United States.

Active ingredients

The drug LISRAYA contains one active pharmaceutical ingredient (API):

`1`	Brepocitinib UNII `3X8387Q25N` - BREPOCITINIB
	Brepocitinib is a Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor. The JAK family comprises cytoplasmic tyrosine kinases that mediate signal transduction of cytokine receptors to influence immune cell function. The relevance of inhibition of specific JAK combinations to therapeutic effectiveness is not known.
	Read more about Brepocitinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LISRAYA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	87211-030

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.